Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2007-10-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Thus, the aim of this study is to assess the effect of MTX on the pharmacokinetic properties of infliximab in 30 patients treated for AS, 15 with MTX, 15 without.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis
NCT00439283
Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis
NCT00936143
Combination Methotrexate and Infliximab
NCT00432432
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
NCT00760669
Methotrexate in Ankylosing Spondylitis (MTX in AS)
NCT00243750
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Infliximab
Infliximab
infliximab
Infliximab +methotrexate
Infliximab +methotrexate
infliximab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
infliximab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Needing anti-TNF drugs
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
PHILIPPE GOUPILLE, MD
Role: PRINCIPAL_INVESTIGATOR
University hospital of Tours, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Jean MINJOZ -Besançon
Besançon, , France
University hospital of Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mulleman D, Lauferon F, Wendling D, Ternant D, Ducourau E, Paintaud G, Goupille P. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther. 2011 Jun 3;13(3):R82. doi: 10.1186/ar3350.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHRR/04/PG-SPAXIM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.